Combined Advanced Targeted Therapy for Inflammatory Bowel Disease

The aim of this retrospective and prospective observational study is to investigate and compare the real-world effectiveness and safety of different dual-target combination therapies in patients with inflammatory bowel disease (IBD). The key questions to be addressed are: In patients with refractory IBD who receive either two biologic agents or one biologic agent plus one small molecule drug, what is the real-world effectiveness and safety of different combination regimens? The researchers will conduct a retrospective analysis of medical records and electronic health data from patients diagnosed with IBD, and will enroll and document patients receiving combination advanced targeted therapy (CATT) for long-term follow-up. The treatments received by these patients are part of routine first-line clinical care or routine rescue clinical care. All treatment decisions were made by treating clinicians according to the standard of care; the investigator did not assign or modify any therapeutic interventions. Data will be collected during a defined follow-up period to compare the real-world effectiveness and safety profiles of different treatment exposure strategies.

NCT Number	NCT07660289
Lead Sponsor	Xijing Hospital of Digestive Diseases
Conditions	IBD (Inflammatory Bowel Disease), Combined Advanced Targeted Therapy, Combination Therapy
Enrollment	117 participants
Start Date	2023-04-20
Primary Completion	2026-05-10 (estimated)
Study Completion	2026-06-10 (estimated)
Updated on ClinicalTrials.gov	2026-06-24